Skip to main content
SpringerLink
Log in
Book cover

Allogeneic Stem Cell Transplantation pp 177–192Cite as

The Role of Transplantation in Favorable-Risk Acute Myeloid Leukemia

  • Chapter
  • First Online:

  • 1443 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

Favorable-risk acute myeloid leukemia (AML) is a subgroup of AML that has been shown to have clinically unique behavior and improved response to therapy based on distinct molecular biology. Traditional post-remission therapies, including intensive consolidation chemotherapy as well as autologous or allogeneic transplantation, have been associated with improved clinical outcomes in this subpopulation. Still, the term favorable-risk incorrectly implies a high likelihood of long-term survival. In fact, most studies show that among patients in first complete remission (CR1) whose disease is characterized by favorable-risk features, long-term survival is achieved in only 40-60%. Notwithstanding that nearly half such patients may sustain relapse, there has been little enthusiasm for autologous or allogeneic stem cell transplantation as post-remission treatment for patients with otherwise favorable disease features on the basis of an excessively high rate of treatment-related morbidity and mortality. Given the remarkable advances in supportive care and immunoprophylaxis with stem cell transplantation over the last several decades and a shift toward risk-adapted therapy, standard post-remission strategies for favorable-risk AML in CR1 are being re-evaluated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mrozek K, Marcucci G, Pascha P et al (2007) Clinical relevance of mutations and gene expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:431-448

    Article  PubMed  CAS  Google Scholar 

  2. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD (1983) Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 309:630-636

    Article  PubMed  Google Scholar 

  3. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD (1986) Acute myelomonocytic leukemia with abnormal eosinophils and inv (16) or t(16;16) has a favorable prognosis. Blood 68:1242-1249

    PubMed  CAS  Google Scholar 

  4. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwars CG, Arthur DC et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336

    Article  PubMed  CAS  Google Scholar 

  5. Larson RA, Le Beau MM, Vardiman JW, Testa JR, Golomb HM, Rowley JD (1983) The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet 10:219-236

    Article  PubMed  CAS  Google Scholar 

  6. Tallman MS, Antersen JW, Schiffer CA, Applebau RR, Feusner JH, Woods WG et al (2002) All-trans retinoic acid in acute promyelocytic leukemia: long term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100(76):1083-1091

    Google Scholar 

  7. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H et al (2003) AML Study Group Ulm (AMLSG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 17:1521-1528

    Article  PubMed  CAS  Google Scholar 

  8. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al (1998) On behalf of the Medical Research Council Adult and Children’s Leukemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333

    PubMed  CAS  Google Scholar 

  9. Look AT (1997) Oncogenic transcription factors in the human acute leukemia. Science 278:1059-1064

    Article  PubMed  CAS  Google Scholar 

  10. Warrell RP Jr, De Thé H, Wang Z-Y, Degos L (1993) Acute promyelocytic leukemia. N Eng J Med 329:177-189

    Article  CAS  Google Scholar 

  11. Wang J, Hoshino T, Redner RI, Kajigaya S, Liu JM (1997) Novel human nuclear receptor co-repressor: cloning and identification as a binding partner for the ETO proto-oncoprotein. Blood 90(Suppl 1):245a. Abstract

    Google Scholar 

  12. Schiller GJ (2005) Clinical and biological features of favorable-risk acute myelogenous leukemia - is favorable-risk AML really favorable? Leukemia 19:326-328

    Article  PubMed  CAS  Google Scholar 

  13. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y (1998) Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CGFalpha) subunit by the leukemia-related PEBO2/CGFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol 18:4252-4261

    PubMed  CAS  Google Scholar 

  14. Fenaux P, Le Deley MC, Castaigne S, et al. European APL 91 Group (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 82:3241-3249

    Google Scholar 

  15. Fenaux P, Chastang C, Chomienne C et al (1995) European APL Group. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy the European experience. Leuk Lymphoma 16:431-437

    Article  PubMed  CAS  Google Scholar 

  16. Tallman MS, Anderson JW, Schiffer CA et al (2002) All-trans retinoic acid acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302

    Article  PubMed  CAS  Google Scholar 

  17. Sanz MA, Lo Coco F, Martin G (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253

    PubMed  CAS  Google Scholar 

  18. George B, Mathews V, Vishwabandhya A, et al (2004) Arsenic trioxide (As2O3) in the treatment of patients with newly diagnosed acute promyelocytic leukemia (APML) - toxicity and outcome [abstract]. Blood 104(pt 1):254a. Abstract 889

    Google Scholar 

  19. Ghavamzadeh A, Alimoghaddam K, Ghaffari H, et al (2004) Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide [abstract]. Blood 104(pt 1):116a. Abstract 396

    Google Scholar 

  20. Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA et al (1991) High dose-cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429-1435

    PubMed  CAS  Google Scholar 

  21. Ferrant A, Frassoni LF, Prentice HG, Cahn JY, Blaise D, Reiffers J et al (1997) on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood 90:2931-2938

    PubMed  CAS  Google Scholar 

  22. Zittoun RA, Mandelli F, Willemze R et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223

    Article  PubMed  CAS  Google Scholar 

  23. Burnett AK, Goldstone AH, Stevens RMF et al (1998) Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet 351:700-708

    Article  PubMed  CAS  Google Scholar 

  24. Cassileth PA, Harrington DP, Appelbaum FR et al (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1666

    Article  PubMed  CAS  Google Scholar 

  25. Bloodfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179

    Google Scholar 

  26. Heil G, Krauter J, Kirchner H et al (2000) Risk adapted induction and consolidation therapy including autologous peripheral blood stem cell transplantation (PBSCT) in adults with de novo AML ≤ 60 years. Blood 96(Suppl 1):522a (Abstr. 224)

    Google Scholar 

  27. Byrd JC, Dogde RK, Carroll A, Baer MR, Edwards C et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775

    PubMed  CAS  Google Scholar 

  28. Tallman MS, Nabhan C, Camitta BM (2005) Acute Myeloid Leukemia. In: Williams ME, Kahn MJ (eds) ASH-SAP American Society of Hematology Self-Assessment Program, 2nd edn. Blackwell, Malden, MA, p 211

    Google Scholar 

  29. Spellberg B, Schiller GJ (1999) Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin North Am 13:919-938

    Article  PubMed  CAS  Google Scholar 

  30. Reiffers J, Stoppa AM, Attal M et al (1996) Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 10:1874-1882

    PubMed  CAS  Google Scholar 

  31. Tsimberidou AM, Stavroyianni N, Viniou N et al (2003) Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97:1721-1723

    Article  PubMed  CAS  Google Scholar 

  32. Harousseau J, Cahn JY, Pignon B, Witz F et al (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 8:2978-2986

    Google Scholar 

  33. Breems DA, Boogaerts MA, Dekker AW et al (2005) Autologous transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukemia in first complete remission: a prospective randomized Dutch-Belgian Hemato-Oncology Co-operative Group (HAVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128:59-65

    Article  PubMed  Google Scholar 

  34. Burnett AK, Wheatley K, Goldstone AH et al (2002) On behalf of the Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118:385-400

    Article  PubMed  Google Scholar 

  35. Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083

    PubMed  CAS  Google Scholar 

  36. Kim DH, Sohn SK, Kim JG et al (2005) Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics as presentation versus disease status at transplantation. Ann Hematol 84:25-32

    Article  PubMed  Google Scholar 

  37. Suciu S, Mandeli F, De Witte T et al (2003) For the EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 102:1232-1240

    Article  PubMed  CAS  Google Scholar 

  38. Keating S, de Witte T, Suciu S et al (1998) The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis on the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Br J Haematol 102:1344-1353

    Article  PubMed  CAS  Google Scholar 

  39. Visani G, Olivieri A, Malagola M et al (2006) Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma 47:1091-1102

    Article  PubMed  CAS  Google Scholar 

  40. Yanada M, Matsuo K, Emi N, Naoe T (2005) Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. Cancer 103:1652-1658

    Article  PubMed  Google Scholar 

  41. Cornelissen JJ, van Putten WLJ, Verdonck LF et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109:3658-3666

    Article  PubMed  CAS  Google Scholar 

  42. Jourdan E, Boiron J-M, Dastugue N et al (2005) Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 23:7676-7684

    Article  PubMed  Google Scholar 

  43. Song KW, Lipton J (2005) Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 36:183-191

    Article  PubMed  CAS  Google Scholar 

  44. Meloni G, Vignetti M, Avvisati G et al (1996) BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 18:693-698

    PubMed  CAS  Google Scholar 

  45. Lioure B, Witz F, Deconninck E et al (1997) Autologous stem cell transplantation (ASCT) represents the best consolidation therapy for acute myelogenous leukemia (AML) in second complete remission (CR): a retrospective study of the GOELAMS group. Blood 90(Suppl 1):384a (Abstr. 1710)

    Google Scholar 

  46. Califaretti N, Davidson M, Abraham R et al (1998) Autologous bone marrow transplant (ABMT) for acute myelogenous leukemia (AML) in second or subsequent remission. Blood 92(Suppl 1):294a (Abstr. 1203)

    Google Scholar 

  47. Linker CA, Damon LE, Ries CA et al (2002) Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 29:297-301

    Article  PubMed  CAS  Google Scholar 

  48. Linker C, George S, Hurd D et al (2001) Autologous stem cell transplantation for acute myeloid leukemia in second remission-CALGB 9620. Blood 98(Suppl 1):689a (Abstr. 2881)

    Google Scholar 

  49. Estey E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25:1908-1915

    Article  PubMed  Google Scholar 

  50. Estey E (2006) General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 43:89-95

    Article  PubMed  Google Scholar 

  51. Kolb HJ, Schattenberg A, Goldman JM et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050

    PubMed  CAS  Google Scholar 

  52. Niederwieser D, Gentilini C, Hegebart U et al (2005) Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Crit Rev Oncol Hematol 56:275-281

    Article  PubMed  Google Scholar 

  53. Cornelissen JJ, Löwenberg B (2005) Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 151-155

    Google Scholar 

  54. Mohty M, De Lavallade H, Ladaique P et al (2005) The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19:916-920

    Article  PubMed  CAS  Google Scholar 

  55. Estey E, de Lima M, Tibes R et al (2007) Prospective feasibility analysis of reduced intensity conditioning regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia and high-risk myelodysplasia syndrome. Blood 109:1395-1400

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Malignancies/Stem Cell Transplant Unit, University of California at Los Angeles, Los Angeles, CA, USA

    Mickey Liao & Gary J. Schiller

Authors
  1. Mickey Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary J. Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Liao, M., Schiller, G.J. (2010). The Role of Transplantation in Favorable-Risk Acute Myeloid Leukemia. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_12

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation